Treating dementia effectively requires a precise understanding of the underlying cause, as the clinical strategies for vascular dementia and Alzheimer disease differ significantly. In a clinical context, Alzheimer disease is characterized by the buildup of toxic proteins, whereas vascular dementia is primarily driven by reduced blood flow and damage to the brain blood vessels. Because these two conditions have different biological foundations, the medications and lifestyle interventions used to manage them are tailored to address these specific issues.
For many patients, a diagnosis of mixed dementia means they exhibit features of both conditions, requiring a combined treatment approach. However, for a pure diagnosis, the focus of medical care follows distinct paths. This guide explains the variations in pharmacological treatments, risk factor management, and the latest disease modifying options available.
what we will discuss in this article
- Specific medications for Alzheimer symptoms vs vascular risk
- The role of blood pressure and cholesterol management in vascular health
- New amyloid targeting infusions for early stage Alzheimer
- Clinical guidelines on using cognitive enhancers in different dementia types
- Lifestyle interventions tailored to vascular and neurodegenerative needs
- The challenges of treating mixed dementia pathology
- emergency guidance for identifying signs of health deterioration
Pharmacological focus in Alzheimer disease
In Alzheimer disease, the primary goal of medication is to support the communication between surviving neurons and, more recently, to clear the toxic proteins responsible for the disease.
Cholinesterase inhibitors
For mild to moderate Alzheimer disease, clinicians typically prescribe cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine. These drugs work by preventing the breakdown of acetylcholine, a chemical messenger in the brain essential for memory and learning. By increasing the levels of this chemical, these medications can temporarily stabilise or slightly improve cognitive function.
NMDA receptor antagonists
As the condition progresses to moderate or severe stages, memantine may be added or used as an alternative. Memantine regulates the activity of glutamate, another brain chemical that can become overactive and toxic to neurons when brain cells are damaged.
Amyloid targeting therapies
In early 2026, disease modifying therapies like lecanemab and donanemab are increasingly used for patients in the very early stages of Alzheimer. These intravenous infusions are designed to physically remove amyloid plaques from the brain, aiming to slow the rate of cognitive decline rather than just managing symptoms.
Cardiovascular management in vascular dementia
The treatment of vascular dementia is fundamentally different because it focuses on the health of the circulatory system rather than the removal of protein plaques.
Unlike Alzheimer disease, there are no medications specifically licensed to improve the cognitive symptoms of pure vascular dementia. Instead, clinical management is centred on preventing further strokes or small vessel damage.
- Blood Pressure Control: Maintaining a healthy blood pressure is the single most important factor in slowing the progression of vascular dementia.
- Cholesterol Management: Statins are frequently prescribed to prevent the buildup of fatty deposits in the arteries that supply the brain.
- Antiplatelet Medication: Drugs like aspirin or clopidogrel are used to reduce the risk of blood clots that could lead to a stroke.
- Diabetes Management: Controlling blood sugar levels is essential to prevent the microvascular damage that often accompanies vascular cognitive impairment.
Comparison of treatment approaches
| Clinical Feature | Alzheimer Disease Focus | Vascular Dementia Focus |
| Primary Medication | Donepezil, Memantine | Blood pressure and statin therapy |
| Targeted Pathology | Amyloid plaques and tau tangles | Arterial health and blood flow |
| Recent Breakthroughs | Amyloid clearing infusions | Advanced vascular risk monitoring |
| Symptom Goal | Enhancing neurotransmission | Preventing further brain tissue death |
| Secondary Focus | Cognitive stimulation therapy | Aggressive cardiovascular lifestyle changes |
The role of cognitive enhancers in vascular dementia
A common clinical question is whether medications used for Alzheimer can help people with vascular dementia.
Current clinical guidelines do not recommend the routine use of cholinesterase inhibitors or memantine for individuals with pure vascular dementia. This is because these drugs target neurochemical deficits specific to Alzheimer pathology. However, if a patient has a mixed diagnosis, meaning they have both Alzheimer and vascular changes, these medications are often prescribed to address the Alzheimer component of their condition. In some cases, a specialist may trial these medications if the patient has significant symptoms that overlap with Alzheimer, but the benefit is generally more limited.
To summarise
The treatments for vascular and Alzheimer dementia are distinguished by their primary targets: one focuses on the brain internal protein environment, while the other focuses on the plumbing of the brain. Alzheimer disease management relies heavily on neurotransmitter support and the emerging field of amyloid clearance. Conversely, vascular dementia management is almost entirely focused on cardiovascular risk reduction to protect remaining brain tissue. Understanding these differences allows clinicians to provide the most effective interventions, whether that involves specialized infusions for Alzheimer or aggressive blood pressure management for vascular health.
emergency guidance
Acute shifts in the condition of a person with any form of dementia require immediate medical attention. Call 999 or seek emergency help if you notice the sudden onset of facial drooping, weakness on one side of the body, or slurred speech, as these are hallmark signs of a stroke. In people with vascular dementia, even small changes in coordination or a sudden, severe headache should be treated with urgency. Additionally, a rapid increase in confusion or a sudden change in behaviour over just a few hours may indicate delirium, often caused by an underlying infection like a urinary tract infection. These situations require a hospital assessment to prevent permanent brain damage.
Can a person take donepezil and blood pressure medicine together?
Yes. For many people with mixed dementia, it is standard clinical practice to take medications that target both the cognitive symptoms of Alzheimer and the vascular risks of the condition.
Is it possible to reverse vascular dementia?
Existing damage to brain tissue from a stroke or small vessel disease cannot be reversed. However, aggressive treatment of risk factors can often slow or stop further decline.
Why aren’t amyloid drugs used for vascular dementia?
Amyloid targeting drugs are specifically designed to remove the plaques found in Alzheimer disease. These plaques are not the cause of vascular dementia, so the drugs would not provide a clinical benefit.
How does exercise help both types of dementia?
Exercise is unique because it supports brain health through multiple pathways: it improves the cardiovascular health vital for vascular dementia and stimulates growth factors that support neurons in Alzheimer.
Should I have my cholesterol checked if I have memory problems?
Yes. Managing cholesterol is a key part of preventing vascular cognitive impairment, which can coexist with other forms of dementia.
What is the best diet for both types?
The Mediterranean and MIND diets are highly recommended as they support both heart health and brain cell resilience.
Authority Snapshot
Dr. Rebecca Fernandez is a UK trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence based approaches such as CBT, ACT, and mindfulness based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well being in 2026. Authority Snapshot
